Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Regeneron Pharmaceuticals (REGN)

Regeneron Pharmaceuticals (REGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 78,931,608
  • Shares Outstanding, K 105,720
  • Annual Sales, $ 14,343 M
  • Annual Income, $ 4,505 M
  • EBIT $ 3,578 M
  • EBITDA $ 4,122 M
  • 60-Month Beta 0.41
  • Price/Sales 5.71
  • Price/Cash Flow 18.45
  • Price/Book 2.62

Options Overview Details

View History
  • Implied Volatility 40.59% (-0.08%)
  • Historical Volatility 30.27%
  • IV Percentile 67%
  • IV Rank 42.52%
  • IV High 60.01% on 04/08/25
  • IV Low 26.22% on 11/26/25
  • Expected Move (DTE 6) 24.45 (3.28%)
  • Put/Call Vol Ratio 0.85
  • Today's Volume 856
  • Volume Avg (30-Day) 1,190
  • Put/Call OI Ratio 0.67
  • Today's Open Interest 47,050
  • Open Int (30-Day) 46,440
  • Expected Range 721.32 to 770.22

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 28 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate 5.96
  • Number of Estimates 6
  • High Estimate 8.00
  • Low Estimate 4.29
  • Prior Year 6.43
  • Growth Rate Est. (year over year) -7.31%

Price Performance

See More
Period Period Low Period High Performance
1-Month
741.90 +0.52%
on 03/13/26
815.00 -8.49%
on 02/17/26
-57.40 (-7.15%)
since 02/13/26
3-Month
718.38 +3.81%
on 01/20/26
821.11 -9.18%
on 01/09/26
+4.48 (+0.60%)
since 12/12/25
52-Week
476.49 +56.51%
on 06/05/25
821.11 -9.18%
on 01/09/26
+65.16 (+9.57%)
since 03/13/25

Most Recent Stories

More News
3 Profitable Stocks We Think Twice About

3 Profitable Stocks We Think Twice About

TOL : 136.69 (-0.96%)
DOCN : 68.63 (+3.64%)
REGN : 745.77 (-0.11%)
Regeneron Science Talent Search 2026 Recognizes America’s Top Young Scientists, Awarding More Than $1.8 Million to High School Seniors for Innovative Research in Computational Mathematics, Neural Science, and Blood Cancer Treatment

TARRYTOWN, N.Y. and WASHINGTON, March 10, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) and Society for Science (the Society) announced that Connor Hill , 17, of State...

REGN : 745.77 (-0.11%)
Olatorepatide Obesity Treatment Licensed by Regeneron Demonstrates Positive Phase 3 Results in Chinese Patients

Patients treated with olatorepatide achieved up to 19% body-weight loss at week 48 Regeneron’s global Phase 3 registrational program to be initiated later this year TARRYTOWN, N.Y., March 09,...

REGN : 745.77 (-0.11%)
1 Nasdaq 100 Stock to Consider Right Now and 2 We Brush Off

1 Nasdaq 100 Stock to Consider Right Now and 2 We Brush Off

AAPL : 250.12 (-2.21%)
TXN : 190.78 (+0.38%)
REGN : 745.77 (-0.11%)
Regeneron Announces Investor Conference Presentation

TARRYTOWN, N.Y., March 05, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ:  REGN ) will webcast management participation at the Barclays 28th Annual Global Healthcare Conference at...

REGN : 745.77 (-0.11%)
Is Regeneron Pharmaceuticals Stock Underperforming the Nasdaq?

Although Regeneron Pharmaceuticals has lagged the Nasdaq over the past year, analysts remain highly bullish about its prospects.

$NASX : 22,105.36 (-0.93%)
REGN : 745.77 (-0.11%)
AMGN : 366.21 (-0.43%)
Dupixent® (dupilumab) Recommended for EU Approval to Treat Chronic Spontaneous Urticaria (CSU) in Young Children with Ongoing Symptoms Despite Treatment

If approved, Dupixent would be the first targeted medicine in the EU indicated for children aged 2 to 11 years with CSU inadequately controlled by standard-of-care antihistamine treatment CSU is...

REGN : 745.77 (-0.11%)
Regeneron Renews Sponsorship of the Regeneron Science Talent Search Through 2036, Committing an Additional $150 Million to Empower the Next Generation of Science and Technology Leaders

Key Takeaways: Regeneron will extend its title sponsorship of the Regeneron Science Talent Search (STS) for a second decade, continuing its partnership with Society for Science to support the United...

REGN : 745.77 (-0.11%)
Dupixent® (dupilumab) Approved in the U.S. as the First and Only Medicine for Allergic Fungal Rhinosinusitis (AFRS)

Approval in adults and children aged 6 years and older supported by Phase 3 trial demonstrating Dupixent significantly reduced nasal signs and symptoms, and systemic corticosteroid use or surgery compared...

REGN : 745.77 (-0.11%)
Is Wall Street Bullish or Bearish on Regeneron Pharmaceuticals Stock?

Regeneron Pharmaceuticals has outperformed the broader market over the past year, and analysts remain highly upbeat about the stock’s growth potential.

XLV : 149.79 (-0.25%)
$SPX : 6,632.19 (-0.61%)
REGN : 745.77 (-0.11%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Buy with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Regeneron is a biotechnology company focused on the discovery, development and commercialization of treatments targeting serious medical conditions. The company's portfolio boasts nine marketed drugs - Eylea, Dupixent, Praluent, Kevzara, Libtayo, Evkeeza, Inmazeb Arcalyst and Zaltrap. The company also...

See More

Key Turning Points

3rd Resistance Point 772.95
2nd Resistance Point 765.97
1st Resistance Point 755.87
Last Price 745.77
1st Support Level 738.78
2nd Support Level 731.80
3rd Support Level 721.70

See More

52-Week High 821.11
Last Price 745.77
Fibonacci 61.8% 689.46
Fibonacci 50% 648.80
Fibonacci 38.2% 608.13
52-Week Low 476.49

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar